Catalog No.
DHD15101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
Leukocyte-endothelial cell adhesion molecule 3, Platelet activation dependent granule-external membrane protein, Granule membrane protein 140, GMP-140, CD62P, SELP, GRMP, PADGEM, CD62 antigen-like family member P, LECAM3, P-selectin, GMRP
Concentration
6.06 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16109
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SelG1, CAS: 1690318-25-2
Clone ID
Crizanlizumab
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease, PMID: 27959701
Crizanlizumab: First Approval, PMID: 31933169
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis, PMID: 30295335
Crizanlizumab, PMID: 32401467
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease, PMID: 32350885
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis, PMID: 32948541
Antibodies to watch in 2020, PMID: 31847708
Crizanlizumab, PMID: 34406730
Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease, PMID: 33332478
Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials, PMID: 32841705
The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management, PMID: 32301178
Antibodies to watch in 2019, PMID: 30516432
Crizanlizumab in Sickle Cell Disease, PMID: 28467874
Drug Therapies for the Management of Sickle Cell Disease, PMID: 32765834
Crizanlizumab in Sickle Cell Disease, PMID: 28467873
Crizanlizumab Prevents Sickle Cell Pain Crises, PMID: 28245319
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease, PMID: 33062233
Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic, PMID: 32873056
Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date, PMID: 31507334
Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease, PMID: 32945013
Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment, PMID: 32208292
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease, PMID: 34235401
P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab, PMID: 33833562
More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease, PMID: 34007618
P-selectin blockade in COVID-19-related ARDS, PMID: 32464083
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease, PMID: 31934320
Two drugs for sickle cell disease, PMID: 32324178
Sickle Cell Disease: Advances in Treatment, PMID: 30559624
What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?, PMID: 32955945
Managing patients with sickle cell disease in primary care, PMID: 32941305
Two New Drugs for Sickle Cell Disease, PMID: 32079792
Treating sickle cell anemia: A new era dawns, PMID: 31925819
Emerging pharmacotherapeutic approaches for the management of sickle cell disease, PMID: 30499731
Advances in Sickle Cell Disease Treatments, PMID: 32520675
Innovative Treatments for Rare Anemias, PMID: 34095760
Antibodies to watch in 2018, PMID: 29300693
Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease, PMID: 31977004
Novartis snaps up Selexys for sickle cell, PMID: 28178263
Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review, PMID: 29296801
Research in Sickle Cell Disease: From Bedside to Bench to Bedside, PMID: 34095767
Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?, PMID: 32722787
Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease, PMID: 34151636
Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options, PMID: 33747397
Review of Medication Therapy for the Prevention of Sickle Cell Crisis, PMID: 30013299
Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review, PMID: 31188815
Sickle cell vaso-occlusion: The dialectic between red cells and white cells, PMID: 33794696
For research use only. Not for human or drug use.
